Experiences with
Ibrutinib2,003 public posts
Want to take advantage of all our features? Just log in!
or
BTK Inhibitor Success Puts Focus on Resistance Mechanisms
Ibrutinib use in a wider range of patients has also revealed the significance of resistance mechanisms and the need for options to manage ibrutinib-resistant cancers.
...
CLL Society Alert - October 23, 2018
m=1120967015548&ca=27a5c5e8-da36-47c0-8638-d063a29a0bd1
Len
-
Hello Friends,
This week we feature our first Clinical Trial Banner that links to a trial offering an existing potential option for patients progressing on ibrutinib. Read about it here.
MUST READ for those on Ibrutinib/Imbruvica - concerning advice in pilot study on lower dosing - incl. danger of starting with a lower dose
[/i]
[i]The ability of ibrutinib to bind BTK is [/i][i][u]not[/u][/i][i] dependent upon the amount of BTK present (as stated in the paper), [/i][i][u]but on the concentration of ibrutinib in the serum[/u][/i][i].
Clinical Trial Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab Untreated CLL & SLL @EU & UK locations
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Phase 3- Radomized Open Label
https://clinicaltrials.gov/ct2/show/study/NCT03462719?